Janney Montgomery Scott LLC Has $2.12 Million Stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA)

Janney Montgomery Scott LLC lessened its stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 29.5% during the third quarter, Holdings Channel reports. The fund owned 305,069 shares of the company’s stock after selling 127,755 shares during the quarter. Janney Montgomery Scott LLC’s holdings in Zevra Therapeutics were worth $2,117,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. International Assets Investment Management LLC raised its holdings in shares of Zevra Therapeutics by 594.0% during the third quarter. International Assets Investment Management LLC now owns 6,940 shares of the company’s stock valued at $48,000 after purchasing an additional 5,940 shares during the period. Price T Rowe Associates Inc. MD acquired a new position in Zevra Therapeutics during the 1st quarter worth approximately $64,000. The Manufacturers Life Insurance Company boosted its holdings in Zevra Therapeutics by 15.2% in the second quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock worth $91,000 after acquiring an additional 2,452 shares in the last quarter. Hunter Associates Investment Management LLC acquired a new stake in Zevra Therapeutics in the third quarter valued at approximately $92,000. Finally, SG Americas Securities LLC bought a new stake in shares of Zevra Therapeutics during the third quarter valued at approximately $105,000. 35.03% of the stock is owned by institutional investors.

Zevra Therapeutics Stock Down 4.4 %

Zevra Therapeutics stock opened at $8.57 on Wednesday. Zevra Therapeutics, Inc. has a fifty-two week low of $3.89 and a fifty-two week high of $9.09. The company has a debt-to-equity ratio of 1.80, a quick ratio of 2.00 and a current ratio of 2.00. The firm’s 50-day simple moving average is $7.94 and its 200 day simple moving average is $6.42. The stock has a market cap of $450.94 million, a PE ratio of -5.10 and a beta of 1.93.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its earnings results on Tuesday, August 13th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.01). The business had revenue of $4.45 million during the quarter, compared to analysts’ expectations of $4.08 million. Zevra Therapeutics had a negative return on equity of 124.85% and a negative net margin of 274.10%. During the same quarter in the previous year, the firm earned ($0.15) EPS. Research analysts predict that Zevra Therapeutics, Inc. will post -1.63 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. William Blair upgraded Zevra Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Maxim Group raised their price objective on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. Canaccord Genuity Group decreased their target price on shares of Zevra Therapeutics from $24.00 to $22.00 and set a “buy” rating for the company in a research report on Wednesday, September 18th. Cantor Fitzgerald restated an “overweight” rating on shares of Zevra Therapeutics in a report on Friday, October 11th. Finally, Roth Mkm lifted their price target on Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Zevra Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $20.83.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.